Agarwal Prashant, Greene Daniel G, Sherman Scott, Wendl Kaitlyn, Vega Leonela, Park Hyunsoo, Shimanovich Roman, Reid Darren L
Drug Product Technologies, Process Development, Amgen, Inc., 360 Binney St, Cambridge, MA 02142, United States.
Drug Product Technologies, Process Development, Amgen, Inc., 360 Binney St, Cambridge, MA 02142, United States.
Eur J Pharm Sci. 2021 Mar 1;158:105689. doi: 10.1016/j.ejps.2020.105689. Epub 2020 Dec 24.
Sustained-release formulations are important tools to convert efficacious molecules into therapeutic products. Hydrogels enable the rapid assessment of sustained-release strategies, which are important during preclinical development where drug quantities are limited and fast turnaround times are the norm. Most research in hydrogel-based drug delivery has focused around synthesizing new materials and polymers, with limited focus on structural characterization, technology developability and implementation. Two commercially available thermosensitive hydrogel systems, comprised of block copolymers of poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) (PLGA) and poly(lactide-co-caprolactone)-b-poly(ethyleneglycol)-b-poly(lactide-co-caprolactone) (PLCL), were evaluated during this study. The two block copolymers described in the study were successfully formulated to form hydrogels which delayed the release of lysozyme (> 20 days) in vitro. Characterization of formulation attributes of the hydrogels like T temperature, complex viscosity and injection force showed that these systems are amenable to rapid implementation in preclinical studies. Understanding the structure of the gel network is critical to determine the factors controlling the release of therapeutics out of these gels. The structures were characterized via the gel mesh sizes, which were estimated using two orthogonal techniques: small angle X-ray scattering (SAXS) and rheology. The mesh sizes of these hydrogels were larger than the hydrodynamic radius (size) of lysozyme (drug), indicating that release through these gels is expected to be diffusive at all time scales rather than sub-diffusive. In vitro drug release experiments confirm that diffusion is the dominating mechanism for lysozyme release; with no contribution from degradation, erosion, relaxation, swelling of the polymer network or drug-polymer interactions. PLGA hydrogel was found to have a much higher complex viscosity than PLCL hydrogel, which correlates with the slower diffusivity and release of lysozyme seen from the PLGA hydrogel as compared to PLCL hydrogel. This is due to the increased frictional drag experienced by the lysozyme molecule in the PLGA hydrogel network, as described by the hydrodynamic theory.
缓释制剂是将有效分子转化为治疗产品的重要工具。水凝胶能够快速评估缓释策略,这在临床前开发中非常重要,因为此时药物数量有限且周转时间短是常态。大多数基于水凝胶的药物递送研究都集中在合成新材料和聚合物上,而对结构表征、技术可开发性和实施的关注有限。在本研究中,对两种市售的热敏水凝胶系统进行了评估,它们由聚(乳酸 - 乙醇酸)-b-聚(乙二醇)-b-聚(乳酸 - 乙醇酸)(PLGA)和聚(丙交酯 - 己内酯)-b-聚(乙二醇)-b-聚(丙交酯 - 己内酯)(PLCL)的嵌段共聚物组成。研究中描述的两种嵌段共聚物成功配制形成了水凝胶,这些水凝胶在体外延迟了溶菌酶的释放(超过20天)。对水凝胶制剂属性如温度、复数粘度和注射力的表征表明,这些系统适合在临床前研究中快速实施。了解凝胶网络的结构对于确定控制治疗剂从这些凝胶中释放的因素至关重要。通过凝胶网孔尺寸对结构进行了表征,使用两种正交技术进行估计:小角X射线散射(SAXS)和流变学。这些水凝胶的网孔尺寸大于溶菌酶(药物)的流体动力学半径(大小),这表明通过这些凝胶的释放在所有时间尺度上预计都是扩散性的,而不是亚扩散性的。体外药物释放实验证实,扩散是溶菌酶释放的主要机制;聚合物网络的降解、侵蚀、松弛、溶胀或药物 - 聚合物相互作用均无贡献。发现PLGA水凝胶的复数粘度比PLCL水凝胶高得多,这与PLGA水凝胶中溶菌酶的扩散率和释放比PLCL水凝胶慢有关。这是由于流体动力学理论所述,溶菌酶分子在PLGA水凝胶网络中经历的摩擦阻力增加。